Seminars in Perinatology
Volume 31, Issue 3 , Pages 135-141 , June 2007

Preeclampsia Recurrence and Prevention

  • Gary A. Dildy III, MD

      Affiliations

    • Department of Obstetrics and Gynecology, LSU Health Sciences Center, New Orleans, LA.
    • Corresponding Author InformationAddress reprint requests to Gary A. Dildy III, MD, Maternal Fetal Medicine Center, St. Mark’s Hospital, 1140 East 3900 South, Suite 390, Salt Lake City, Utah 84124.
    • ,
  • Michael A. Belfort, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, UT.
    • ,
  • John C. Smulian, MD, MPH

      Affiliations

    • Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ.

References 

  1. Sibai BM, Ewell M, Levine RJ, et al. The Calcium for Preeclampsia Prevention (CPEP) Study Group Risk factors associated with preeclampsia in healthy nulliparous women. Am J Obstet Gynecol. 1997;177:1003–1010
  2. Why Mothers Die (Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1994-1996). London: HMSO; 1998;
  3. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance–United States, 1991-1999. MMWR Surveill Summ. 2003;52:1–8
  4. Ujah IA, Aisien OA, Mutihir JT, et al. Factors contributing to maternal mortality in north-central Nigeria: a seventeen-year review. Afr J Reprod Health. 2005;9:27–40
  5. Trupin LS, Simon LP, Eskenazi B. Change in paternity: a risk factor for preeclampsia in multiparas. Epidemiology. 1996;7:240–244
  6. ACOG practice bulletin (Diagnosis and management of preeclampsia and eclampsia). American College of Obstetricians and Gynecologists; 2002;Number 33, January
  7. Campbell DM, MacGillivray I, Carr-Hill R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol. 1985;92:131–140
  8. van Rijn BB, Hoeks LB, Bots ML, et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol. 2006;195:723–728
  9. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol. 1991;165:1408–1412
  10. Sibai BM, Taslimi MM, el-Nazer A, et al. Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia. Am J Obstet Gynecol. 1986;155:501–509
  11. Sibai BM, Ramadan MK, Chari RS, et al. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol. 1995;172:125–129
  12. Sullivan CA, Magann EF, Perry KG, et al. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations. Am J Obstet Gynecol. 1994;171:940–943
  13. Chames MC, Haddad B, Barton JR, et al. Subsequent pregnancy outcome in women with a history of HELLP syndrome at ≤28 weeks of gestation. Am J Obstet Gynecol. 2003;188:1504–1507discussion 1507-1508
  14. Adelusi B, Ojengbede OA. Reproductive performance after eclampsia. Int J Gynaecol Obstet. 1986;24:183–189
  15. Chesley LC. Eclampsia: the remote prognosis. Semin Perinatol. 1978;2:99–111
  16. Sibai BM, Sarinoglu C, Mercer BM. Eclampsia (VII. Pregnancy outcome after eclampsia and long-term prognosis). Am J Obstet Gynecol. 1992;166:1757–1761discussion 1761-1763
  17. Trogstad L, Skrondal A, Stoltenberg C, et al. Recurrence risk of preeclampsia in twin and singleton pregnancies. Am J Med Genet A. 2004;126:41–45
  18. Hnat MD, Sibai BM, Caritis S, et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol. 2002;186:422–426
  19. Brosens I. A study of the spiral arteries of the decidua basalis in normotensive and hypertensive pregnancies. J Obstet Gynaecol Br Commonw. 1964;71:222–230
  20. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683
  21. Grahame-Clarke C. Human cytomegalovirus, endothelial function and atherosclerosis. Herpes. 2005;12:42–45
  22. Parra A, Ramirez-Peredo J. The possible role of prolactin in preeclampsia: 2001, a hypothesis revisited a quarter of century later. Med Hypotheses. 2002;59:378–384
  23. Acikgoz S, Harma M, Harma M, et al. Comparison of angiotensin-converting enzyme, malonaldehyde, zinc, and copper levels in preeclampsia. Biol Trace Elem Res. 2006;113:1–8
  24. Arbogast BW, Leeper SC, Merrick RD, et al. Which plasma factors bring about disturbance of endothelial function in pre-eclampsia?. Lancet. 1994;343:340–341
  25. Lorentzen BEM, Clausen T, Henriksen T. Fasting serum free fatty acids and triglycerides are increased before 20 weeks of gestation in women who later develop preeclampsia. Hypertens Pregnancy. 1994;13:103–109
  26. Easterling TR, Benedetti TJ. Preeclampsia: a hyperdynamic disease model. Am J Obstet Gynecol. 1989;160:1447–1453
  27. Bosio PM, McKenna PJ, Conroy R, et al. Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol. 1999;94:978–984
  28. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol. 1998;179:1359–1375
  29. Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 2001;344:867–872
  30. Skjaerven R, Vatten LJ, Wilcox AJ, et al. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. Br Med J. 2005;331:877
  31. Haig D. Altercation of generations: genetic conflicts of pregnancy. Am J Reprod Immunol. 1996;35:226–232
  32. Duley L, Henderson-Smart DJ, Knight M, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev CD004659. 2004;
  33. Coomarasamy A, Honest H, Papaioannou S, et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003;101:1319–1332
  34. Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2006;3:CD001059
  35. Spatling L, Spatling G. Magnesium supplementation in pregnancy (A double-blind study). Br J Obstet Gynaecol. 1988;95:120–125
  36. Sibai BM, Villar MA, Bray E. Magnesium supplementation during pregnancy: a double-blind randomized controlled clinical trial. Am J Obstet Gynecol. 1989;161:115–119
  37. Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev. 2006;3:CD003402
  38. Meher S, Duley L. Garlic for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2006;3:CD006065
  39. Meher S, Duley L. Progesterone for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev CD006175. 2006;
  40. Rumbold A, Duley L, Crowther C, et al. Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev CD004227. 2005;
  41. Poston L, Briley AL, Seed PT, et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet. 2006;367:1145–1154
  42. Rumbold AR, Crowther CA, Haslam RR, et al. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med. 2006;354:1796–1806
  43. Riyazi N, Leeda M, de Vries JI, et al. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol. 1998;80:49–54
  44. Kupferminc MJ, Fait G, Many A, et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy. 2001;20:35–44
  45. Arias F, Romero R, Joist H, et al. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med. 1998;7:277–286
  46. Mello G, Parretti E, Fatini C, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005;45:86–91
  47. Widmer M, Villar J, Benigni A, et al. Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol. 2007;109:168–180
  48. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Br Med J. 2005;330:565
  49. Conde-Agudelo A, Belizan JM. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. Br J Obstet Gynaecol. 2000;107:75–83
  50. Sibai BM, Hauth J, Caritis S, et al. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units Hypertensive disorders in twin versus singleton gestations. Am J Obstet Gynecol. 2000;182:938–942
  51. Stamilio DM, Sehdev HM, Morgan MA, et al. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?. Am J Obstet Gynecol. 2000;182:589–594
  52. Abi-Said D, Annegers JF, Combs-Cantrell D, et al. Case-control study of the risk factors for eclampsia. Am J Epidemiol. 1995;142:437–441
  53. Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132:171–196
  54. Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106:260–267
  55. Tucker MJ, Berg CJ, Callaghan WM, et al. The Black-White disparity in pregnancy-related mortality from 5 conditions: differences in prevalence and case-fatality rates. Am J Public Health. 2007;97:247–251

PII: S0146-0005(07)00036-5

doi: 10.1053/j.semperi.2007.03.005

Seminars in Perinatology
Volume 31, Issue 3 , Pages 135-141 , June 2007

Article Tools